tbuckley/cabot-search huggingface dataset:
Prospective characterization of circulating tumor cells (CTCs) in head and neck cancer patients receiving definitive radiotherapy.
Authors: Michael Joseph Eblan, Ja Hye Myung, Joseph M Caster, Seth M. Miller, Dominic T. Moore, Bhishamjit S. Chera, Seungpyo Hong, Andrew Wang
Journal: Journal of Clinical Oncology (2015)

e22040 Background: Circulating tumor cells (CTCs) are an important biomarker in several cancers, but little data exist in head and neck malignancies. More importantly, no data exist on how CTCs change with definitive radiotherapy treatment regimens. The purpose of this exploratory, prospective correlative study is to fill this knowledge gap using a novel and highly sensitive CTC capture technique (UiChip). Methods: Patients with a diagnosis of non-metastatic head and neck cancer (HNC) undergoing definitive radiation, with or without chemotherapy, were eligible for enrollment. Peripheral blood was collected prospectively at 5 time points, including at baseline prior to starting RT, at the first week, mid-point and final week during treatment, and at least 4 weeks after completion of RT. Quantification of CTCs was performed with UiChip CTC technology. The primary endpoint was to measure changes in CTCs pre- and post- RT. Results: 25 patients were enrolled (median age 58, 80% male, 40% non-smokers, 50% HPV/p16 positive, and 38% node negative) and 16 completed radiotherapy treatment with collection of sequential CTC counts. 84% and 8% of patients received concurrent or induction chemotherapy, respectively. CTCs were successfully detected in all patients pre-treatment. CTCs showed a significant decline throughout the treatment course in patients with complete clinical and/or radiographic response. All 3 patients with known partial response or pathologic residual disease showed an elevation in CTCs mid-treatment (Table). Conclusions: We have demonstrated that UiChip can capture CTCs in a diverse population of head and neck cancer. Our pilot data suggest that CTC kinetics during treatment may be a predicative biomarker for radiotherapy response. Median CTC counts per mL peripheral blood (median % of pre-treatment baseline count). Pre-RT Mid-RT End-RT Complete Responders to RT (N = 13) 104 IQR: 24-556 23 (24%) IQR: 11-59 (10-52%) 14 (1%) IQR: 7-20 (0-19%) Partial Responders to RT (N = 3) 40 IQR: 26-453 100 (771%) IQR: 55-204 (386-818%) 34 (130%) IQR: 24-73 (67-206%) IQR: Interquartile Range
NOVEL PRECLINICAL ASSESSMENT OF TRANSCATHETER MITRAL VALVE REPLACEMENT BY MICRO COMPUTED TOMOGRAPHY: MCT IMAGING GUIDED HISTOPATHOLOGICAL EVALUATION
Authors: Armando Tellez, Krista N. Hemming, Amit Vasanji, Zacahry J. Kaufman, Brett A. Hoover, Muralidhar Padala, Dane A. Brady, Serge Rousselle
Journal: Journal of the American College of Cardiology (2017)
VARIATION IN THE USE OF DIRECT ORAL ANTICOAGULANTS AND ASSOCIATED COST IMPLICATIONS: FINDINGS FROM THE MEDICAL EXPENDITURE PANEL SURVEY 2010 TO 2013
Authors: Benjamin Rodwin, Khurram Nasir, Joseph Salami, Erica Spatz, Javier Valero-Elizondo, Salim Virani, Ron Blankstein, Michael Blaha, Nihar Desai
Journal: Journal of the American College of Cardiology (2017)
Abstract 10114: Cardiovascular Magnetic Resonance Measurement of Myocardial Extracellular Volume by T1 Mapping Differentiates Athlete's Heart From Hypertrophic Cardiomyopathy
Authors: Peter P Swoboda, Adam K Mcdiarmid, Bara Erhayiem, David A Broadbent, Gemma K Lyall, Rosalind E Lancaster, Laura E Dobson, David P Ripley, Tarique A Musa, Pankaj Garg, Carrie Ferguson, Stephen P Page, John P Greenwood, Sven Plein
Journal: Circulation (2015)

Introduction: Athletes who train regularly can develop left ventricular (LV) hypertrophy, which can be difficult to differentiate from hypertrophic cardiomyopathy (HCM), the leading cause of sudden cardiac death in young athletes. Cardiovascular magnetic resonance (CMR) T1 and extracellular volume (ECV) mapping provide quantitative assessment of myocardial composition. Hypothesis: ECV can differentiate athletic from pathological remodelling. Methods: 35 athletes, 25 HCM patients and 35 volunteers underwent 3.0T CMR protocol including 5b(3s)3b Modified Look-Locker Inversion (MOLLI) T1 maps before and 15 minutes after administration of 0.15mmol/kg intravenous gadobutrol. Native T1 and ECV were measured for each subject and each segment of the American Heart Association model. Results: Native T1 and ECV were both significantly lower in athletes than HCM (1182.8±38.1ms vs 1264.6±50.3ms, P&lt;0.001 and 23.2±2.9% vs 32.3±5.9%, P&lt;0.001 respectively). On receiver operator curve analysis the area under the curve (AUC) to differentiate HCM from athlete for native T1 was 0.91 and ECV 0.95. The AUC to differentiate indeterminate 8-15mm thick segments (Figure) were native T1 0.83, ECV 0.92 and segment thickness 0.80 (P&lt;0.001 for all). The diagnostic accuracy of ECV was superior to native T1 and segment thickness (P=0.001 for both). The optimal cut-off to diagnose HCM in an indeterminate segment was ECV&gt;24.7% (sensitivity 91.7% &amp; specificity 83.2%) and native T1&gt;1226ms (sensitivity 60.0% &amp; specificity 96.7%). Conclusions: ECV measurement by CMR is able to distinguish HCM and athletic remodelling with high diagnostic accuracy and has a potential role in the exclusion of HCM in athletes presenting with left ventricular hypertrophy. Figure: ROC curves for segmental wall thickness (mm), native T1 (ms) and ECV (%) for the detection of HCM against athletes in intermediate wall thickness segments (8-15mm thick). AUCs were 0.80, 0.83, and 0.92 respectively (P&lt;0.001 for all).
Use of a novel radio-sensitizer for treatment of GBM.
Authors: John Lloyd Gainer, Jason Sheehan, James Mitchell Larner, David Randolph Jones
Journal: Journal of Clinical Oncology (2015)

2031 Background: Trans sodium crocetinate (TSC) was developed to increase tissue oxygenation. Since hypoxia may enhance radiation resistance, we tested TSC along with radiation therapy (RT) in GBM in a Phase I/II trial. 59 patients received TSC in an open GBM clinical trial together with TMZ and RT (www.clinicaltrials.gov , NCT01465347). Although final data for the first 2 years will not be available until late summer 2015, this abstract discusses results from 18 clinical sites which are available at 21 months. Methods: 59 patients with newly diagnosed GBM were enrolled between Jan. 2012 and March 2013 into a Phase I/II trial. All patients received standard of care RT and TMZ. In the Phase I portion of the trial TSC was initially administered 3x/week at half-dose to 3 patients prior to RT. Subsequently, 6 additional patients received full dose TSC for 6 weeks in combination with RT. No dose-limiting toxicities were identified in the 9 patients on the Phase I portion of the trial. Fifty additional patients were enrolled in the Phase II trial at full dose TSC in combination with TMZ and RT. Four weeks after completion of RT, all patients resumed TMZ for 5 days every 4 weeks, but no further TSC was administered. All patients were followed with bi-monthly neurologic exams, MRI’s, KPS scores and Quality of Life questionnaires. Results: At a minimum of 21 months follow-up since the diagnosis of GBM: Radiologic Response: Pseudo progression occurred in numerous patients. Complete responses were observed in 10% of patients. Survival: Overall Survival: 38.2%. Survival did not correlate with initial tumor resection: 6/15 patients with original complete resection alive at 21 months and 8/15 biopsy-only patients. Quality Of Life: Both KPS scores and questionnaires indicate continued high QOL. Safety: Excellent patient toleration of dosing TSC with TMZ. Conclusions: TSC was well tolerated in combination with RT and TMZ. Our data at a minimum follow-up of 21 months suggest that TSC may promote radio-sensitization since there was a large incidence of pseudo-progression, with complete tumor regression in about 10% of patients and Overall Survival of 38.2%, This is one of the first demonstrations that a type of oxygen radio-sensitizer can be of benefit, being possible through the novel mechanism of TSC. Clinical trial information: NCT01465347.
Survey of disease and treatment-related symptoms in outpatients with invasive cancer of the breast, prostate, lung, or colon/rectum (E2Z02, the SOAPP study)
Authors: M. Fisch, J. W. Lee, J. Manola, L. Wagner, V. Chang, P. Gilman, K. Lear, L. Baez, C. Cleeland
Journal: Journal of Clinical Oncology (2009)

9619 Background: The full spectrum and impact of symptoms experienced by ambulatory patients (pts) in medical oncology clinics throughout their care trajectory is poorly understood. Methods: This large prospective study by the Eastern Cooperative Oncology Group (ECOG) enrolled pts with invasive cancer of the breast, prostate, colon/rectum or lung regardless of phase of care or stage of disease. The study was conducted between 3/06 and 5/08 at multiple academic (n=7) and community (n=32) medical oncology clinics. Pre-defined sampling algorithms were used to reduce selection bias. At baseline and again 4 weeks later, pts completed a 25-item measure of symptoms and functional interference (M.D. Anderson Symptom Inventory-ECOG). Patients’ providers simultaneously prioritized their symptoms. Results: 3124 patients were enrolled (90% from community clinics) and 3077 were analyzable with 1524 breast (50%), 715 colorectal (23%), 518 lung (17%), and 320 prostate (10%) pts. The most prevalent moderate-to-severe symptoms of the full cohort at baseline (B) and follow-up (F) were: fatigue (B34% to F32%), disturbed sleep (B27% to F21%), drowsiness (B22% to F21%), hair loss (B20% to F19%), pain (B19% to F18%), dry mouth (B19% to F15%), and numbness/tingling (B19% to F17%). At baseline, 40% of the cohort had at least 3 moderate-to-severe symptoms and 36% had this attribute at follow-up. Clinician perception of symptoms was strongly correlated with patient symptom survey results regardless of disease site, race, or ethnicity. Of the 849 pts receiving anti-cancer treatment for metastatic disease, half had 2 or more metastatic sites with 75% receiving cytotoxic chemotherapy. Clinicians judged lung cancer patients’ symptoms to be the most difficult to manage (p&lt;0.01). Conclusions: Non-pain symptoms, particularly fatigue and sleep disturbance, are a major source of symptom distress in ambulatory medical oncology practice. Overall, symptom burden remains substantial and difficult to resolve. These data will help guide future interventional studies. No significant financial relationships to disclose.
Long-term prognosis of patients with gastric cancer in stage UICC I without lymph-node involvement.
Authors: Christoph Treese, Pedro Sanchez, Ioannis Anagnostopoulos, Peter M. Schlag, Michael Kruschewski, Oliver Haase, Gerd Berger, Hendrik Blaeker, Michael Hummel, Severin Daum
Journal: Journal of Clinical Oncology (2013)

e15068 Background: Despite radical oncologic resection with extended lymph node removal, patients with adenocarcinoma of the gastro-esophageal junction or stomach in UICC stage I show only a 5-year survival of 60-80% (Hölscher et al, 2009; Siewert et al. 1998). The aim of this retrospective study was to analyze the long-term survival of caucasian patients with early stage gastric cancer as for this population exist only sparse data. Patients with lymph-node involvement were not included as this parameter is a well-known negative prognostic marker. Methods: Tissue specimens and clinical data from patients with gastric cancer treated in the years 1993 to 2010 at the Charité, Berlin were collected retrospectively. Patients with stage T1 and T2 pN0M0 gastric cancer treated only by surgery including D1- and D2-lymphnode dissection were included in this study. Patients without relapse were followed-up for a minimum period of 24 months. Results: 97 patients (w = 36, m = 61, age 29-90 years) with a follow-up time from 6 to 208 months were identified. The 5-year survival was 94.85% (for details, see Table). Conclusions: The present data indicate a much better prognosis (5-year survival of 95%) of UICC I patients than previously described (60-80%). In harmony with other studies, our data demonstrate that R1, L1 or V1 resection seem to be a risk factor for recurrence whereas signet-ring differentiation was not found as a risk factor in our patient cohort. Ongoing work involves a broad panel of immunohistochemical markers to select prognostic expression profiles which help to identify patients with early gastric cancer at higher risk. This study was supported by the Berliner Krebsgesellschaft, grant DAFF201101. [Table: see text]
Medullary breast carcinoma: Outcomes and prognosis with the utilization of chemotherapy
Authors: G. H. Perkins, M. C. Green, L. P. Middleton, S. H. Giordano, S. M. Garcia, E. A. Strom, N. R. Schechter, P. Allen, T. A. Buchholz, G. N. Hortobagyi
Journal: Journal of Clinical Oncology (2004)

671 Background: Medullary carcinoma of the breast is an uncommon histological type consisting of poorly differentiated cells surrounded by a prominent lymphoid stroma. It is also suggested that these lesions have good prognosis and therefore may not benefit from systemic therapy. We therefore report on our experience with this tumor type. Methods: 143 evaluable patients treated between 1980–2003 at UTMDACC were retrospectively reviewed on an IRB approved protocol. Pathology was reviewed. Outcomes were analyzed by administration of chemotherapy, use of hormonal therapy, pathologic size, and nodal status. Log-rank statistics were used for overall-, local-regional failure-free, and distant metastasis free- survival. Results: Mean age at diagnosis was 44 years (range 24–84)with a mean follow-up of 9 years (range 0.16- 23.3). 71% of patients recieved chemotherapy (n=102) with 88% having a doxorubicin-based regimen. 72% were ER-. 27 had positive nodes with only 6 patients having 4 or more nodes positive. 5 and 10 yr OS, LRFFS, and DMFS for all patients was 82%/75%, 86%/86%, and 84%/80% respectively. Improvement in 5 and 10 yr OS and DMFS was noted with chemotherapy (86%/79%) vs no chemoherapy (72%/66% P=.08) and ( 81%/81% vs 71%/71% P=.08). No improvement was noted with adjuvant hormonal therapy (n=21)(P=.5). 5 and 10 yr OS rates decreased with increasing tumor size with tumors 1 cm or less having 100%/100% vs tumors 1–3cm having 83%/83%, and tumors 3 cm or larger having 74%/69% values (p=.13). LN- patients likewise had improved 5 and 10 yr OS rates (87%/80% vs 75%/61%)(P=.07). No significant difference in OS, LRFFS, or DMFS was noted after stratification of lymph nodes (1–3 vs 4+). Conclusions: Patients with medullary breast cancer benefited from the use of adjuvant chemotherapy. Limited patient numbers preclude comment on adjuvant hormones. Tumors less than 1 cm were most favorable as were those without nodal metastasis. In our series, patients with + nodes and tumor size greater than 1 cm had prognosis similar to that ascribed to invasive ductal carcinoma NOS and may benefit from systemic regimens. Larger datasets should be examined to further clarify therapy recommendations. No significant financial relationships to disclose.
In Chronic Lymphocytic Leukemia the Gain of the Short Arm of Chromosome 2 Is Highly Associated with an Unmutated IGHV status, 11q/ATM Deletion, SF3B1 Mutation and a Complex Karyotype
Authors: Claudia Haferlach, Sabine Jeromin, Anna Stengel, Manja Meggendorfer, Melanie Zenger, Wolfgang Kern, Torsten Haferlach
Journal: Blood (2016)
Safety and efficacy of retreating follicular non-Hodgkin’s lymphoma (NHL) with <sup>90</sup>Y ibritumomab tiuxetan
Authors: J. Shah, D. Harrough, W. Saville, J. Mueh, J. Lister, S. Jasthy, M. Gregory, C. McKay, R. Krumdieck, A. Forero
Journal: Journal of Clinical Oncology (2006)

17528 Background: There is no data regarding safety and efficacy of treating follicular NHL patients with a second course of 90 Y ibritumomab tiuxetan (Zevalin). Methods: Patients with follicular NHL who received 2 courses of Zevalin therapy were identified nationally, and data was retrospectively collected. Results: 10 patients (pts) (mean age 62.5 years, 48–91) were identified. Prior to the first Zevalin, all pts received chemotherapy (mean 2.4 courses, 1–5), 3/10 auto-PBSCT, and 4/10 external beam radiotherapy(ebRT). After the initial course of treatment, the mean time to nadir for the anemia was 7.9 weeks (wks)(4–13), neutropenia was 6.7 wks (4–10); and thrombocytopenia was 5.2 wks (4–8). 1 pt required growth factor support and transfusions; 2 had an incomplete recovery of platelet count at 23 and 30 wks (76,000 and 126,000/μl). Hematologic toxicity and grades are in the table below. Prior to the second course of Zevalin 2 pts received ebRT, 1 received 131 I tositumomab, and 3 received chemotherapy (1–5 regimens). The median time to the second Zevalin course was 613 days (183–1,300). After the second course of Zevalin, the mean time to nadir for the anemia was 8.2 wks (2–25); neutropenia was 6.7 wks (4–10); and thrombocytopenia was 5.5 wks (4–7). 4/10 pts required growth factor support, 2 required transfusions, 3 had incomplete recovery of platelet count and early progression, 2 pts had a maximum recovery of their platelet count at 29 and 40 wks (143,000 and 144,000/μl). There were no infectious or bleeding complications with either course of Zevalin. No secondary myelodysplastic syndrome or acute leukemia were reported. Conclusions: Retreating patients with follicular NHL with a second course of Zevalin is tolerable with substantial evidence of clinical efficacy. This data warrants further evaluation of Zevalin retreatment in a clinical trial. [Table: see text] [Table: see text]
TRENDS AND USE OF ECHOCARDIOGRAPHY IN PATIENTS WITH STAPHYLOCOCCUS AUREUS BACTEREMIA: AN ANALYSIS USING THE NATIONWIDE INPATIENT SAMPLE (NIS) DATA
Authors: Prakrity Urja, Arjun Theertham, Mukund Kumar, Nina Zook, Kellen O'Neill, Ryan Walters, Ram Belbase, Renuga Vivekanandan, Venkata Alla
Journal: Journal of the American College of Cardiology (2017)
SERIAL ASSESSMENT OF THROMBOGENICITY AND HEMODYNAMICS IN PATIENTS WITH TYPE II DIABETES OBSERVED IN A CLINICAL RESEARCH UNIT: EVIDENCE FOR CIRCADIAN CHANGES IN CLOT FORMATION
Authors: Paul A. Gurbel, Kevin Bliden, Christopher McLeod, Tushar Sharma, Rahul Chaudhary, Udaya Tantry
Journal: Journal of the American College of Cardiology (2017)
A phase I trial of the safety and immunogenicity of a multi-epitope folate receptor alpha peptide vaccine used in combination with cyclophosphamide in subjects previously treated for breast or ovarian cancer.
Authors: Pashtoon Murtaza Kasi, Kimberly Kalli, Matthew Stephen Block, Timothy J. Hobday, Travis J. Dockter, Vera J. Suman, Courtney L. Erskine, Daniel W. Visscher, Glynn Wilson, Barath Shreeder, Keith L. Knutson
Journal: Journal of Clinical Oncology (2015)

e14028 Background: Folate receptor alpha (FRα) is overexpressed by multiple cancers, including breast and ovarian cancers. Endogenous T-cell immunity to each of five degenerate peptides from FRα (FR30, FR56, FR76, FR113 and FR238) has been demonstrated in both breast and ovarian cancer patients, suggesting the feasibility of targeting FRα via a vaccine approach. Metronomic oral cyclophosphamide (CTX) has been demonstrated to reduce immunosuppressive T regulatory cells (Tregs) and might thereby improve vaccine efficacy. We therefore conducted a Phase I clinical trial testing safety and immunogenicity of a multi-epitope FRα peptide vaccine after 1 cycle of CTX. Methods: Twenty-two patients with breast or ovarian cancer who had undergone standard surgery and adjuvant treatment were treated with 1 cycle of CTX (given days 1-7 and 15-22 of 28). Following this, patients were vaccinated intradermally at 3 sites with a mixture of the 5 FRα peptides on day 1 of a 28 day cycle for a maximum of 6 vaccination cycles. Patients were monitored for toxicity at each visit. Peripheral blood samples were collected for immune monitoring purposes at baseline, at the completion of each cycle of treatment, and at during observation at 3, 6, and 12 months after vaccine completion. The number of Tregs was assessed via flow cytometry, and the number of antigen-specific T cells was assessed via ELIspot. Results: Of 22 patients evaluable for toxicity, one patient developed a grade 3 injection site reaction. Grade 2 reactions were observed in 14 patients and included lymphopenia (5), neutropenia (4), injection site reactions (2), and leukopenia (2). The median frequency of Tregs did not significantly change after CTX use. However, FRα-specific T cell responses were observed in 20 of 21 patients with immune response data. Of these, 16 of 16 patients with observation data had demonstrable T cell responses persisting into the observation phase. Conclusions: Vaccine treatments were associated with mild to moderate toxicity. FRα specific T cell responses were induced in the majority of patients and frequently persisted after completion of vaccine therapy. Clinical trial information: NCT01606241.
LONG-TERM EFFECTS OF RIGHT VENTRICULAR PACING ON LEFT VENTRICULAR SYSTOLIC AND DIASTOLIC FUNCTION AND SYNCHRONY BY STRAIN IMAGING IN PATIENTS WITH NORMAL BASELINE LEFT VENTRICULAR EJECTION FRACTION
Authors: Shuang Liu, Oral Waldo, Tripta Kaur, Ali Ahoui, Luis Scott, Tasneem Z. Naqvi
Journal: Journal of the American College of Cardiology (2017)
LEFT ATRIUM UNDIFFERENTIATED PLEOMORPHIC SARCOMA MIMICKING SEPTAL ASYMMETRIC HYPERTROPHIC CARDIOMIOPATHY
Authors: David Alfonso Aguilar Pulido, Pedro Gerardo Davila Flores, Jesus Bueno Campa, Joaquin Gomez, Francisco Javier Leon Hernandez, Karim Juarez Escobar
Journal: Journal of the American College of Cardiology (2017)
MOLECULAR AUTOPSY OF PLAQUE EROSION-INDUCED SUDDEN CARDIAC DEATH IN YOUNG ADULTS (18-35 YEARS OLD)
Authors: Liang Guo, Sho Torii, Emanuel Harari, Hiroyoshi Mori, Matthew Kutyna, Samantha Smith, Ryan Braumann, Robert Kutys, Renu Virmani, Aloke Finn
Journal: Journal of the American College of Cardiology (2017)
The Outcome of 129 Korean Children with Hemophagocytic Lymphohistiocytosis.
Authors: Hoi Soo Youn, Joon Sup Song, Ho Joon Im, Jong Jin Seo, Hyung Nam Moon, Byoung Gyu Park, Thad T. Kim, Hyoung Jin Kang, Hee Young Shin, Hyo Seop Ahn, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Dae Chul Jeong, Bin Cho, Hack Ki Kim, Mee Jeong Lee, Eun Sil Park, Hwang Min Kim, Young Tak Lim, Heung Sik Kim, Chuhl Joo Lyu, Sun Young Kim, Jun Eun Park, Young Ho Lee, Chur Woo You, Ji Yoon Kim, Im Ju Kang, Kun Soo Lee, Hoon Kook, Tai Ju Hwang
Journal: Blood (2006)
BOTH THE NOVEL NMR BIOMARKER OF INFLAMMATION, GLYCA, AND HS-CRP ARE INDEPENDENT AND ADDITIVE PREDICTORS OF FUTURE CARDIOVASCULAR EVENTS AMONG PATIENTS UNDERGOING CORONARY ANGIOGRAPHY: RESULTS FROM THE INTERMOUNTAIN HEART COLLABORATIVE STUDY
Authors: J. Brent Muhlestein, Heidi May, Oxana Galenko, Kirk Knowlton, James Otvos, Margery Connelly, Donald Lappe, Jeffrey Anderson
Journal: Journal of the American College of Cardiology (2017)
INFLUENCE OF FAMILY HISTORY OF AORTIC DISEASE ON TYPE B AORTIC DISSECTION
Authors: Sherene Shalhub, Maral Ouzounian, Eduardo Bossone, Kevin Harris, Patrick O'Gara, Anil Bhan, Patroklos Pappas, Anthony DiScipio, Clayton Kaiser, Edward Chen, Christoph Nienaber, Daniel Montgomery, Eric Isselbacher, Kim Eagle, Mark Lindsay, Arturo Evangelista
Journal: Journal of the American College of Cardiology (2017)
IMPLEMENTATION OF A WIDEBAND LATE GADOLINIUM ENHANCEMENT CARDIAC MAGNETIC RESONANCE PROTOCOL TO IMPROVE ASSESSMENT OF MYOCARDIAL SCAR IN PATIENTS WITH IMPLANTABLE CARDIOVERTER DEFIBRILLATORS
Authors: Amita Singh, Keigo Kawaji, Roderick Tung, Karima Addetia, Noreen Nazir, Akhil Narang, Javed Zaidi, Ginny O'Keefe Baker, Roberto Lang, Amit Patel
Journal: Journal of the American College of Cardiology (2017)